Eastern Cooperative Oncology Group

Medicine & Life Sciences

1. Organized Financing 100%
2. Antineoplastic Protocols 92%
3. Neoplasms 70%
4. Clinical Protocols 63%
5. Multiple Myeloma 39%
6. Growth and Development 33%
7. Research Personnel 32%
8. Lymphoma, Large B-Cell, Diffuse 30%
9. Survival 28%
10. Occupational Groups 23%
11. Biostatistics 20%
12. Authorship 19%
13. Clinical Trials 18%
14. Therapeutics 16%
15. Thalidomide 16%
16. Patient Care 15%
17. Self-Help Groups 15%
18. Hematologic Neoplasms 15%
19. Manuscripts 15%
20. Rituximab 14%
21. Karyotype 13%
22. Quality of Health Care 13%
23. Cytogenetics 13%
24. Precursor Cell Lymphoblastic Leukemia-Lymphoma 13%
25. Population 12%
26. Treatment Failure 12%
27. Dexamethasone 12%
28. Methylation 12%
29. Leukemia 10%
30. Clinical Studies 9%
31. Morbidity 7%
32. Mortality 6%
33. Combined Modality Therapy 6%
34. Natural History 5%
35. Antineoplastic Agents 5%